A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label study designed to evaluate the safety and efficacy of
neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA
non-small cell lung cancer.
The primary endpoint: pCR rate The second endpoint: MPR, DFS, MRD